tiprankstipranks
Advertisement
Advertisement

HK:2105 Stock Latest News

Laekna Unveils HK$56 Million Insider-Backed Share Buyback Plan
Company AnnouncementsLaekna Unveils HK$56 Million Insider-Backed Share Buyback Plan
15d ago
2105
Laekna Streamlines Company Secretary and Governance Roles After HKEX Qualification Approval
PremiumCompany Announcements
Laekna Streamlines Company Secretary and Governance Roles After HKEX Qualification Approval
17d ago
2105
Laekna Grants Vasque Bio Global Rights to LAE118 Outside Greater China
PremiumCompany Announcements
Laekna Grants Vasque Bio Global Rights to LAE118 Outside Greater China
1M ago
2105
Laekna Shareholders Approve All Resolutions at 2026 AGM
PremiumCompany Announcements
Laekna Shareholders Approve All Resolutions at 2026 AGM
1M ago
2105
Laekna Sets 2026 AGM to Approve 2025 Results and Share Issuance Mandate
PremiumCompany Announcements
Laekna Sets 2026 AGM to Approve 2025 Results and Share Issuance Mandate
2M ago
2105
Laekna grants 15.3 million RSUs under 2024 share award scheme
PremiumCompany AnnouncementsLaekna grants 15.3 million RSUs under 2024 share award scheme
2M ago
2105
Laekna’s Breast Cancer Drug LAE002 Hits Phase III PFS Goal, NDA in China Planned
Premium
Company Announcements
Laekna’s Breast Cancer Drug LAE002 Hits Phase III PFS Goal, NDA in China Planned
3M ago
2105
Laekna Advances Obesity Candidate LAE102 With Positive Phase I Data
Premium
Company Announcements
Laekna Advances Obesity Candidate LAE102 With Positive Phase I Data
4M ago
2105
Laekna Announces Positive Phase I Results for Obesity-Targeted Antibody LAE102
PremiumCompany Announcements
Laekna Announces Positive Phase I Results for Obesity-Targeted Antibody LAE102
4M ago
2105
Laekna Sets March 2026 Board Meeting to Approve 2025 Annual Results
PremiumCompany Announcements
Laekna Sets March 2026 Board Meeting to Approve 2025 Annual Results
4M ago
2105
Laekna Wins FDA Acceptance of IND for New PI3Kα Inhibitor LAE118
PremiumCompany Announcements
Laekna Wins FDA Acceptance of IND for New PI3Kα Inhibitor LAE118
6M ago
2105
Laekna Doses First Subject in Phase I Trial of Metabolic Drug Candidate LAE103
PremiumCompany Announcements
Laekna Doses First Subject in Phase I Trial of Metabolic Drug Candidate LAE103
7M ago
2105
Laekna Doses First Patient in Phase I Multiple-Dose Expansion Study of Obesity Drug LAE102
PremiumCompany AnnouncementsLaekna Doses First Patient in Phase I Multiple-Dose Expansion Study of Obesity Drug LAE102
7M ago
2105
Laekna Completes Enrollment for Phase III Breast Cancer Trial
Premium
Company Announcements
Laekna Completes Enrollment for Phase III Breast Cancer Trial
7M ago
2105
Laekna, Inc. Updates Nomination and Governance Committee
Premium
Company Announcements
Laekna, Inc. Updates Nomination and Governance Committee
7M ago
2105
Laekna, Inc. Announces Board of Directors and Committee Roles
PremiumCompany Announcements
Laekna, Inc. Announces Board of Directors and Committee Roles
7M ago
2105
Laekna, Inc. Updates Governance Committee Terms
PremiumCompany Announcements
Laekna, Inc. Updates Governance Committee Terms
7M ago
2105
Laekna, Inc. Partners with Qilu Pharma for Exclusive Licensing of LAE002 in China
PremiumCompany Announcements
Laekna, Inc. Partners with Qilu Pharma for Exclusive Licensing of LAE002 in China
8M ago
2105
Laekna, Inc. Advances Breast Cancer Treatment with Promising Clinical Study
PremiumCompany Announcements
Laekna, Inc. Advances Breast Cancer Treatment with Promising Clinical Study
9M ago
2105
Laekna, Inc. Advances Obesity Treatment with LAE102 Study
PremiumCompany AnnouncementsLaekna, Inc. Advances Obesity Treatment with LAE102 Study
9M ago
2105
Laekna, Inc. Reports Positive Phase I Results for Obesity Treatment
Premium
Company Announcements
Laekna, Inc. Reports Positive Phase I Results for Obesity Treatment
10M ago
2105
Laekna, Inc. Completes Successful Share Placement to Boost R&D
Premium
Company Announcements
Laekna, Inc. Completes Successful Share Placement to Boost R&D
10M ago
2105

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >